A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Läs mer

Introduction to hand and foot dermatitis

Läs mer

Hot topics in atopic dermatitis: Hear it from the experts

Läs mer

Why Don’t We Strike Early, Strike Strong?

Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens

Läs mer

COPD Research Forum

In this COPD Research Forum, leading healthcare professionals discuss critical topics such as IL-33, lung function trajectories, and mucus plugging in COPD.

Läs mer

Rhino Rounds International 2024 - Interview

Läs mer

Highlights från ERS 2024, Wien, 7-11 september

Symposierapporter Sanofi

Sanofi har med hjälp av AI-verktyg förkortat texterna till sammanfattningar samt översatt dem till svenska.

Läs mer

Slowly Expanded Lesions

A candidate biomarker for smoldering neuroinflammation in MS.

Läs mer

Multiple sclerosis progression: time for a new mechanism-driven framework

Paper by Tanja Kuhlmann et al.

Läs mer

Smouldering multiple sclerosis

Läs mer

The Important role of microglia in Multiple Sclerosis

Läs mer

Rhino Rounds International - Moving forward in CRSwNP

Läs mer

Utbildning

Filtera

Filtera

Innehållstyp

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Introduction to hand and foot dermatitis

Hot topics in atopic dermatitis: Hear it from the experts

Why Don’t We Strike Early, Strike Strong?

COPD Research Forum

Rhino Rounds International 2024 - Interview

Highlights från ERS 2024, Wien, 7-11 september

Slowly Expanded Lesions

Multiple sclerosis progression: time for a new mechanism-driven framework

Smouldering multiple sclerosis

The Important role of microglia in Multiple Sclerosis

Rhino Rounds International - Moving forward in CRSwNP

Arbetar du inom vården?